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Decreased mortality of ischaemic heart disease among carriers of
haemophilia
A Srämek, M Kriek, FR Rosendaal
Summary
Background Coagulation plays an important part in
ischaemic cardiovascular disease. Results of studies have
shown that extremes in hypocoagulability protect against
ischaemic cardiovascular disease. We have investigated
overall mortality and death from cardiovascular causes in
carriers of haemophilia, who in most cases have mildly
decreased coagulability without clinical signs.
Methode We followed-up a cohort of 1012 mothers of all
known people with haemophilia in the Netherlands from birth
to death, or the end-of-study date (41 984 person years of
follow-up). We obtained vital Status and causes of death, if
deceased, and compared overall and cause-specific mortality
in our cohort with that in the general Dutch female population
adjusted for age and calendar period by calculating the
standardised mortality ratio (SMR).
Findings Overall mortality was reduced by 22% (261
observed deaths, 333-74 expected; SMR 0-78 [95% Cl
0-69-0-88]). Deaths from ischaemic heart disease were
reduced by 36% (39 observed deaths, 60-53 expected; SMR
0-64 [0-47-0-88]). We did not note decreased mortality for
cerebral stroke (ischaemic and haemorrhagic combined) (28
observed deaths, 36-82 expected; SMR 0-76 [0-53-1-10]).
A separate analysis of these two types of stroke was not
possible. Women in our cohort had an increased risk of
death from extracranial haemorrhage (5 observed deaths,
0-18 expected; SMR 27-78 [8-49-58-18]); however, the
number of deaths from this cause was much Iower than that
for ischaemic heart disease.
Conclusion The results show that a mild decrease in
coagulability has a protective effect against fatal ischaemic
heart disease.
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Introduction
Severely impaired haemostasis protects against ischaemic
heart disease. In a study with long follow-up, patients with
haemophilia A or B (clotting factor VIII or IX deficiency,
respectively) had an 80% reduction in the risk of fatal
ischaemic heart disease.1 Oral anticoagulants and platelet
inhibitors are used to induce coagulation defects and can
successfully prevent ischaemic events.2'3 Increased
coagulability, on the other hand, has been shown to be a
risk factor for ischaemic cardiovascular disease,"
although results are not consistent.7·8
Patients with haemophilia have concentrations of
clotting factor at the extreme Iower end of the ränge and
they have spontaneous haemorrhages. Haemophilia is a
genetic recessive X-linked trait. Therefore, although men
are affected, women are heterozygous carriers and can
transmit the disorder to their sons. Because they have one
unaffected allele, carriers have concentrations of clotting
factor VIII or IX of about 50% of normal and, hence,
decreased coagulability.''10 However, if carriers do have an
increased bleeding tendency, it is mild.11
To determine whether a mild, in most cases
asymptomatic, decreased coagulability protects against
ischaemic cardiovascular events, we compared overall and
cause-specific mortality in carriers of the recessive gene
for haemophilia with that in the general population. To
make this comparison, we assessed death rates of mothers
of haemophilia patients between 1861 and 2001.
Methods
Study population
We included mothers of people with haemophilia
identified in nationwide surveys of haemophilia patients
done in the Netherlands in 1985 and 1992.12·13 These
surveys were sent to all registered patients in the
Netherlands with haemophilia (1263 in 1992).
Information on type and severity of haemophilia was
ascertained through haemophilia treatment centres.1 Since
Napoleonic times, all Dutch citizens are registered with
municipal authorities in their town. We searched these
registries using name and address information from the
surveys to obtain information on vital Status of mothers of
patients with haemophilia. Follow-up lasted until death or
the end of the study (Nov l, 2000), whichever came first.
Causes of death
Causes of death were made available by the Netherlands
Central Bureau of Statistics, which receives a copy of all
death certificates and routinely codes them using the
International Classification of Diseases (ICD). These
causes of death were only available from 1950 onward.
For analysis, we recoded codes used in ICD5-9 to match
those used in ICD10.'"' Causes of death were
subsequently grouped into infections (ICD10: AOO-B99),
malignant disease (ICD10: COO-97), respiratory-tract
diseases (ICD 10: JOO-99), cardiovascular diseases
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(ICD10: 100-99), and external causes such äs traffic
accidents, suicide, homicide (ICD10: SOO-Z99).
Cardiovascular disease was further subdivided into
ischaemic heart disease (ICD10: 120-25) and
cerebrovascular diseases (ICD10: 160-69, haemorrhagic
and ischaemic cerebrovascular diseases combined). We
also analysed deaths attributable to coagulation disorders
and extracranial haemorrhages (ICD10: D66-69) and
death from thrombosis and pulmonary embolism
(ICD10: 126, 180, and 182). We ascertained the cause of
death of nearly all mothers who had died between 1950
and 2000 (243 of 247, 98%).
Statistical analysis
We compared overall and cause-specific mortality for our
cohort with that in the general Dutch female population
after adjustment for age and calendar period. Adjustment
was done by calculating the standardised mortality ratio
(SMR), which is the ratio of the observed number of
(cause-specific) deaths and the expected number of
deaths based on the mortality rates of the reference
population. Expected mortality is established by
multiplication of the total number of years lived by the
study population per category of age and calendar period
with the corresponding (cause-specific) mortality rates of
the reference population. Mathematically, the SMR is the
ratio of the standardised incidence rates. Mortality rates
are published every year by the Netherlands Central
Bureau of Statistics. We calculated 95% CI for the SMR
presuming a Poisson distribution for the observed number
of deaths.20 Since the carriers in our study were selected
through their offspring, and therefore had to live at least
until reproductive age, the first two decades of life were
ignored to avoid underestimation of the SMR. To
determine differences in mortality by type of haemophilia
and severity, we used Cox regression analysis. For the
SMR determination of the overall mortality we used exact
age and date of death for the mothers.
For population calculations, we used 20-year
(1840-1900) and 10-year (1900-2000) calendar time
intervals, and for age we used 5-year intervals äs supplied
by the Netherlands Central Bureau of Statistics. For the
cause-specific SMR, calendar periods were divided into
5-year intervals. For reasons of privacy, individual causes
of death are not made available in The Netherlands.
Because it was impossible to obtain informed consent for
an individuaPs cause of death to be released, they were
made available in a grouped fashion with a minimum of
three women per cell (eg, by type of haemophilia, by age,
by severity).
Role of the funding source
The Sponsor of the study had no role in the study design,
data collection, data analysis, data Interpretation, or in the
writing of the report.
Results
1012 women born between 1861 and 1968 were included
in this study. We could not ascertain vital Status for
33 people (3-3%), in most cases because of emigration.
For all other women, we did establish vital Status at the
end-of-study date. Of 979 mothers, 849 (87%) had one or
more sons with haemophilia A, and 130 (13%) with
haemophilia B. With respect to severity, 388 (40%)
carried severe haemophilia (ie, clotting factor VIII or IX
concentrations <1 lU/dL in the son), 170 (17%) carried
moderate to severe haemophilia (concentrations of
1-5 lU/dL), 409 (42%) carried mild haemophilia
(5-25 lU/dL). The severity of haemophilia was unknown
Number of participants Dead
Type of chlld's haemophilia
Haemophilia A
Haemophilia B
















































*Seventy not known for 12 womsn.
Table 1: General characteristics of mothers of haemophilia
patients
for the sons of 12 (1%) women. 261 women (27%) had
died before the end of study date (Nov l, 2000), with age
at death between 30 and 98 years. General characteristics
are shown in table l.
979 women were included in the analysis of overall
mortality (41 984 person years of follow-up). During
follow-up, 261 women had died, whereas 333-74 deaths
were expected based on the population figures (table 2).
The reduction in overall mortality was 22% (SMR 0-78
[95% CI] 0-69-0-88). The reduction in overall mortality
remained unchanged when we ignored the first three or
four decades of life in the analysis (0-81 [0-72-0-92]; and
0-83 [0-73-0-94], respectively). In fact, mortality was
reduced most, in absolute numbers, in the oldest age
groups: 217 of all 261 deaths occurred after age 60 years,
whereas 252-65 deaths were expected (0-86 [0-75-0-98]).
The reduction in overall mortality remained unchanged
when subgroups of haemophilia were analysed (ie, by type
and severity of haemophilia) and was noted in all calendar
periods—1880-1940 (SMR 0-43 [95% CI 0-22-0-68]),
1940-70 (0-73 [0-54-1-07]), and 1970-2000 (0-83 [0-72
toO-95].
The analysis of cause-specific mortality was restricted
to the period 1950-2001, and included 965 women
(34 548 person-years), of whom 247 (26%) died during
follow-up (cause of death could not be obtained for four
women). Table 3 shows cause-specific mortality for the
major causes of deaths in our cohort compared with those
in the general female population adjusted for age and
calendar period. We did not note differences in causes of
death between the two groups, except for ischaemic heart
disease (SMR 0-64 [95% CI 0-47-0-88]). This reduction
was present in both time periods (1950-79, 0-55
[0-27-0-93]; 1980-2000, 0-69 [0-45-0-98]). The risk
reduction for ischaemic heart disease death was observed
Person Observed
years deaths
Type of child's haemophilia
All 41984 261
Haemophilia A 36432 228
Haemophilia B 5552 33
Severity of child's haemophilia


















Table 2: Overall mortality in carriers of haemophilia
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247 300-86 0-82 (0-72-0-93)
*Extracranial haemorrhages. flncludes four women for whom cause of death is
not known and 33 non-major causes of death.
Table 3: Cause-specific mortality in carriers of haemophilia
in all age groups, although precise age-specific estimates
could only be obtained in elderly people, where most
deaths occurred—for those aged over 60 years (0-66
[0-46-0-89]), for those over 70 years (0-56 [0-36-0-80],
and for those over 80 years (0-52 [0-27-0-84]). No
evidently decreased mortality was noted for haemorrhagic
and ischaemic stroke combined (0-76 [0-53-1-10]). ICD
coding did not allow us to look at these two types of stroke
separately. For coagulation disorders and extracranial
haemorrhages, we noted a sharply increased mortality
(27-8 [8-5-58]), although the absolute increase was small
(five cases). For thrombosis and pulmonary embolism the
study group was small, although the data were compatible
with a reduced rate of death. We noted no differences in
overall and cause-specific mortality by type or severity of
haemophilia (data not shown).
Discussion
Carriers of haemophilia have a 22% reduction in overall
mortality, and a 36% reduction in death from ischaemic
heart disease. There is an increased risk of death of
haemorrhage, which, however, is much rarer than fatal
ischaemic heart disease. We noted no clear effect of being
a carrier of haemophilia on the incidence of stroke.
Unfortunately, ICD codes do not allow a separate analysis
of ischaemic and haemorrhagic stroke, where one would
expect opposite effects.
Average factor VIII and IX concentrations of 50%
of normal have been reported in carriers, irrespective of
the severity of haemophilia they carry. Such
concentrations usually do not lead to an increased
bleeding tendency. However, because of unbalanced
lyonisation, clotting factor concentrations can ränge from
22% to 116% of normal.'·22 An increased bleeding
tendency has been established in people with low levels of
clotting factor, especially after dental and surgical
interventions or after childbirth." Coagulation factor
concentrations less than 30% of normal, however, arise in
only 2% of the carriers,23 and therefore our findings
indicate a reduced risk of fatal ischaemic heart disease
even for mildly reduced factor VIII or IX concentrations.
The women in this study were selected through their
offspring. Although haemophilia can arise in some
patients from a new mutation either in women or in men,
only about 40% of patients are isolated haemophilia
patients (ie, patients without a family history of the
disease) and about a fifth of the mothers of these isolated
patients are expected not to be carriers.24 The fraction of
non-carriers in our study is, therefore, small (around 8%).
The presence of a few non-carriers in the study implies
that the true reduction in mortality in carriers will only be
more pronounced than that reported here, although the
difference is likely to be negligible.
Results of our study show a substantial decrease in
overall mortality in carriers of haemophilia. This decrease
is largely accounted for by a decreased number of deaths
from ischaemic heart disease; however, several other
factors could explain the additional risk reduction. First,
only women with offspring were selected in this study, and
their risk of death was compared with that in the general
female population, which includes women without
children. Investigators in a Norwegian study noted a
higher mortality in nulliparous women than in women
who had had children.25 Because only a minority of the
female general population remains childless, this
explanation accounts for only a small part of the reduction
in deaths. Moreover, in a methodological study aimed at
assessing the magnitude of this effect, we compared
mortality rates of pedigrees of probands randomly
selected from the phonebook and mortality rates of
spouses of various patients, with rates in the general
population.26 We invariably noted SMRs of one for
pedigrees and spouses of random probands, both of which
were cohorts ascertained through living individuals.
Another explanation for the reduced mortality in our
cohort is that the birth of a child with haemophilia might
lead women to refrain from subsequent pregnancies,
thus reducing the risk of death associated with
childbirth.10 Reported maternal mortality by the Central
Bureau of Statistics during pregnancy and delivery,
however, is so low, at 3-6 per l million women in 1995,
that a noticeable effect on our results is extremely
unlikely. Finally, the presence of a severe hereditary
disease in the family could promote health-conscious
behaviour within the family. Again, although an effect
cannot be ruled out, we believe it implausible, because we
observed a risk reduction in people with sons with mild
haemophilia, a mild disorder unlikely to affect lifestyle.
Furthermore, in a previous study we noted that the risk
profile for Cardiovascular disease in patients with
haemophilia does not differ greatly from that in the
general male population.27
Our results accord with those of other studies in which
decreased coagulability has been associated with a
protective effect against myocardial infarction. Such an
effect has also been reported in patients with
haemophilia,27 and in individuals with blood group O
compared with non-O (group O is accompanied by lower
concentrations of von Willebrand factor and factor VIII).28
A decreased tendency for occluding arterial thrombosis
was also noted in pigs with a complete deficiency of von
Willebrand factor.29 Furthermore, high concentrations of
clotting factor VIII have been shown to be related to
thrombotic risk, although this was less clear for arterial
than for venous thrombosis.5'30 Results of our study
underline the crucial role of haemostasis in the end stage
of ischaemic heart disease, (ie, the formation of an
occluding arterial thrombus).
We noted a reduced overall mortality in carriers of
haemophilia, most probably resulting from a protective
effect of low concentrations of clotting factor VIII and IX
on ischaemic heart disease. Because concentrations of
these factors vary between carriers, we cannot infer
whether a gradually increasing protective effect occurs äs
concentrations decrease, or whether there is a threshold
effect. Now, in many countries measurement of clotting
factor concentrations in carriers of haemophilia is
common practice. In the future, investigators will be able
to assess the protective effect of various degrees of
reduced concentrations of clotting factors.
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